JOP20170046B1 - صيغة جونادوتروبين سائلة مستقرة - Google Patents

صيغة جونادوتروبين سائلة مستقرة

Info

Publication number
JOP20170046B1
JOP20170046B1 JOP/2017/0046A JOP20170046A JOP20170046B1 JO P20170046 B1 JOP20170046 B1 JO P20170046B1 JO P20170046 A JOP20170046 A JO P20170046A JO P20170046 B1 JOP20170046 B1 JO P20170046B1
Authority
JO
Jordan
Prior art keywords
stable liquid
formulation
liquid gonadotropin
gonadotropin formulation
stabilization
Prior art date
Application number
JOP/2017/0046A
Other languages
English (en)
Inventor
Helen Ulrika Sjogren
Charlotte Hojer-Pedersen
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806922&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20170046(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Application granted granted Critical
Publication of JOP20170046B1 publication Critical patent/JOP20170046B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

يتعلق الاختراع الحالي بصفة عامة بتثبيت صيغ منبهة للغدد التناسلية، وبخاصة بصيغ سائلة من منبهات الغدد التناسلية. يتحقق التثبيت بواسطة توليفة معينة من السواغات، يفضل الأرجينين والميثيونين. في نموذج مفضل، لا تشتمل الصيغة على محلول منظم.andnbsp;
JOP/2017/0046A 2016-02-24 2017-02-19 صيغة جونادوتروبين سائلة مستقرة JOP20170046B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1603280.7A GB201603280D0 (en) 2016-02-24 2016-02-24 Stable liquid gonadotropin formulation

Publications (1)

Publication Number Publication Date
JOP20170046B1 true JOP20170046B1 (ar) 2021-08-17

Family

ID=55806922

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2017/0046A JOP20170046B1 (ar) 2016-02-24 2017-02-19 صيغة جونادوتروبين سائلة مستقرة

Country Status (36)

Country Link
US (4) US10792334B2 (ar)
EP (3) EP3791860B1 (ar)
JP (3) JP6932710B2 (ar)
KR (1) KR102756413B1 (ar)
CN (2) CN113398250B (ar)
AR (1) AR107782A1 (ar)
AU (2) AU2017222292B2 (ar)
BR (1) BR112018015166A2 (ar)
CA (1) CA3012759A1 (ar)
CL (1) CL2018001984A1 (ar)
CO (1) CO2018007810A2 (ar)
DK (2) DK3419595T3 (ar)
EA (1) EA036383B1 (ar)
ES (2) ES2862193T3 (ar)
FI (1) FI3791860T3 (ar)
GB (1) GB201603280D0 (ar)
HR (2) HRP20210367T1 (ar)
HU (2) HUE064432T2 (ar)
IL (1) IL260626B2 (ar)
JO (1) JOP20170046B1 (ar)
LT (2) LT3419595T (ar)
MA (2) MA43686B1 (ar)
MD (2) MD3791860T2 (ar)
MX (1) MX381709B (ar)
MY (1) MY193138A (ar)
PH (1) PH12018501688B1 (ar)
PL (2) PL3791860T3 (ar)
PT (2) PT3419595T (ar)
RS (2) RS64929B1 (ar)
SG (1) SG11201806140SA (ar)
SI (2) SI3419595T1 (ar)
TN (1) TN2018000284A1 (ar)
TW (1) TWI755377B (ar)
UA (1) UA123107C2 (ar)
WO (1) WO2017144659A1 (ar)
ZA (1) ZA201804944B (ar)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
US20190262314A1 (en) * 2018-02-26 2019-08-29 Slayback Pharma Llc Ready-to-use dexmedetomidine compositions
WO2020071912A1 (en) * 2018-10-02 2020-04-09 Innocore Technologies B.V. Extended release formulations of human chorionic gonadotropin (hcg)
CN112451652A (zh) * 2020-12-07 2021-03-09 苏州智核生物医药科技有限公司 一种重组人促甲状腺素注射液
WO2022197963A1 (en) * 2021-03-19 2022-09-22 Pfizer Inc. Long-acting growth hormone compositions
CN118209739A (zh) * 2024-03-19 2024-06-18 厦门宝太和瑞生物技术有限公司 促黄体生成素检测试剂盒
KR102821987B1 (ko) * 2024-10-24 2025-06-26 에이디텍 주식회사 베타 코어 단편 hCG를 유효성분으로 포함하는 난임 치료용 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2198299C (en) 1996-02-28 2000-05-02 Yuhei Abe Card holder-type balance display
TW518235B (en) 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
IL140984A0 (en) * 1998-07-23 2002-02-10 Lilly Co Eli Fsh and fsh variant formulations, products and methods
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
CA2700662C (en) * 2007-11-01 2015-10-13 Merck Serono S.A. Lh liquid formulations
KR20210049186A (ko) 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
EP2412385A1 (en) 2008-02-08 2012-02-01 BioGeneriX AG Liquid formulation of FSH
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
US8329649B2 (en) 2008-11-04 2012-12-11 Aska Pharmaceutical Co., Ltd. Aqueous composition containing follicle-stimulating hormone and histidine
WO2011099036A2 (en) * 2010-02-12 2011-08-18 Intas Biopharmaceuticals Limited Liquid formulation of follicle stimulating hormone
WO2011108010A2 (en) 2010-03-05 2011-09-09 Intas Biopharmaceuticals Limited A thermostable liquid formulation of gonadotropins
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
AP2016009159A0 (en) * 2013-11-12 2016-04-30 Cadila Healthcare Ltd Formulation for gonadotropins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation

Also Published As

Publication number Publication date
AR107782A1 (es) 2018-06-06
HUE064432T2 (hu) 2024-03-28
IL260626A (ar) 2018-09-20
JP6932710B2 (ja) 2021-09-08
PL3419595T3 (pl) 2021-06-14
CO2018007810A2 (es) 2018-10-22
WO2017144659A1 (en) 2017-08-31
AU2017222292A1 (en) 2018-07-26
EA036383B1 (ru) 2020-11-03
HUE053492T2 (hu) 2021-06-28
MD3791860T2 (ro) 2024-03-31
US10792334B2 (en) 2020-10-06
EP3419595A1 (en) 2019-01-02
TW201733612A (zh) 2017-10-01
KR20180114178A (ko) 2018-10-17
SI3419595T1 (sl) 2021-04-30
DK3791860T5 (da) 2024-08-19
US20230372447A1 (en) 2023-11-23
PH12018501688B1 (en) 2023-08-02
RS61604B1 (sr) 2021-04-29
AU2017222292B2 (en) 2021-12-16
ES2966262T3 (es) 2024-04-19
PH12018501688A1 (en) 2019-05-27
FI3791860T3 (fi) 2024-01-11
CL2018001984A1 (es) 2018-09-14
JP2023164573A (ja) 2023-11-10
US20190060409A1 (en) 2019-02-28
DK3791860T3 (da) 2023-12-18
CN108883061A (zh) 2018-11-23
NZ744294A (en) 2024-08-30
CN108883061B (zh) 2021-06-08
TN2018000284A1 (en) 2020-01-16
TWI755377B (zh) 2022-02-21
BR112018015166A2 (pt) 2018-12-18
LT3419595T (lt) 2021-03-10
MX2018010201A (es) 2019-06-06
US11666635B2 (en) 2023-06-06
EP3791860A1 (en) 2021-03-17
CN113398250B (zh) 2024-02-23
UA123107C2 (uk) 2021-02-17
ES2862193T3 (es) 2021-10-07
MA52595A (fr) 2021-03-17
AU2022200027A1 (en) 2022-02-03
MD3419595T2 (ro) 2021-06-30
MA43686B1 (fr) 2021-03-31
EP3419595B1 (en) 2021-01-06
IL260626B1 (en) 2023-04-01
EA201891905A1 (ru) 2019-02-28
PT3419595T (pt) 2021-03-29
EP4257149A2 (en) 2023-10-11
CA3012759A1 (en) 2017-08-31
IL260626B2 (en) 2023-08-01
PL3791860T3 (pl) 2024-03-18
SG11201806140SA (en) 2018-08-30
MY193138A (en) 2022-09-26
US20250352621A1 (en) 2025-11-20
PT3791860T (pt) 2023-12-15
US20210236600A1 (en) 2021-08-05
DK3419595T3 (da) 2021-03-29
GB201603280D0 (en) 2016-04-13
JP2021191760A (ja) 2021-12-16
EP4257149A3 (en) 2023-12-20
US12447196B2 (en) 2025-10-21
KR102756413B1 (ko) 2025-01-16
SI3791860T1 (sl) 2024-01-31
JP2019507153A (ja) 2019-03-14
EP3791860B1 (en) 2023-10-11
MA43686A (fr) 2019-01-02
CN113398250A (zh) 2021-09-17
MA52595B1 (fr) 2023-12-29
RS64929B1 (sr) 2023-12-29
HRP20231477T1 (hr) 2024-03-01
ZA201804944B (en) 2023-02-22
HRP20210367T1 (hr) 2021-04-16
LT3791860T (lt) 2023-12-11
MX381709B (es) 2025-03-13

Similar Documents

Publication Publication Date Title
PH12018501688A1 (en) Stable liquid gonadotropin formulation
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
CL2018000320A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
CR20160499A (es) Composiciones estables de yodo no en complejo y métodos de uso
MX2021015789A (es) Reduccion de la viscosidad de formulaciones farmaceuticas.
MY187047A (en) Selective pyy compounds and uses thereof
MX2017003121A (es) Formulaciones de anticuerpos.
EA201991798A1 (ru) Стабильные при хранении составы
MX2017007178A (es) Formulaciones liquidas estables de virus de vacuna.
AR098168A1 (es) Formulación estable de insulina glulisina
CL2015002897A1 (es) Inhibidores de bace1
PH12018501243B1 (en) Pharmaceutical composition comprising anti-human tslp receptor antibody
CL2019002729A1 (es) Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico.
TW201613557A (en) Stable aqueous recombinant protein formulations
PH12018502089A1 (en) Pharmaceutical composition of dapagliflozin
CL2019002733A1 (es) Formulaciones de clorhidrato del ácido 1-amino-1-ciclopropanocarboxílico.
MX2019011545A (es) Composiciones celulares y de andamio inyectables.
MX2016015261A (es) Dispersion solida de allisartan isoproxilo y su composicion.
JOP20200126B1 (ar) طرق استخدام وتركيبات تحتوي على دولاجلوتيد
GEAP202215306A (en) Formulations of copanlisib
MX2019010330A (es) Formulaciones con mejora de la estabilidad.
GEP20196977B (en) Pharmaceutical formulations of vildagliptin
CL2016000542A1 (es) Composición que comprende hidroxipropil quitosano junto con excipientes y/o adyuvantes farmacéuticamente aceptables; útil en el tratamiento de la onicomicosis.
UA106905U (uk) Фармацевтична композиція
UA93017U (uk) Препарат "нановулін-врх"